- call +1-201-465-4211
- email sales@mrinsights.biz
Multiple myeloma is a cancer that forms in a type of white blood cell that is called a plasma cell. Plasma cells help to fight infections by making antibodies. Multiple myeloma causes cancer cells to accumulate in the bone marrow, where they crowd out healthy blood cells. Rather than produce helpful antibodies, the cancer cells produce abnormal proteins that can cause complications. For people with multiple myeloma who require treatment, a number of treatments are available to help control the disease.
Scope of the Report:
This report focuses on the Multiple Myeloma Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Cancer cells have higher levels of proteasome activity are more sensitive to the proapoptotic effects of proteasome inhibition than normal cells, which makes the proteasome a therapeutic target in multiple myeloma. Proteasome inhibitor treatment is preferred after there is a treatment failure with the conventional approach.
The worldwide market for Multiple Myeloma Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
Amgen
Johnson & Johnson
Celgene
Takeda Pharmaceutical
Novartis
Daiichi Sankyo
Merck
AB Science
Teva
PharmaMar
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Immunomodulatory drugs (IMiDs)
Proteasome inhibitors
Chemotherapy
Histone deacetylase inhibitor (HDAC inhibitor)
Steroids (corticosteroids)
Market Segment by Applications, can be divided into
Men
Women
There are 15 Chapters to deeply display the global Multiple Myeloma Drugs market.
Chapter 1, to describe Multiple Myeloma Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Multiple Myeloma Drugs, with sales, revenue, and price of Multiple Myeloma Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Multiple Myeloma Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Multiple Myeloma Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Multiple Myeloma Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Multiple Myeloma Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Immunomodulatory drugs (IMiDs)
1.2.2 Proteasome inhibitors
1.2.3 Chemotherapy
1.2.4 Histone deacetylase inhibitor (HDAC inhibitor)
1.2.5 Steroids (corticosteroids)
1.3 Market Analysis by Applications
1.3.1 Men
1.3.2 Women
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Amgen
2.1.1 Business Overview
2.1.2 Multiple Myeloma Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Amgen Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Johnson & Johnson
2.2.1 Business Overview
2.2.2 Multiple Myeloma Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Johnson & Johnson Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Celgene
2.3.1 Business Overview
2.3.2 Multiple Myeloma Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Celgene Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Takeda Pharmaceutical
2.4.1 Business Overview
2.4.2 Multiple Myeloma Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Takeda Pharmaceutical Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Novartis
2.5.1 Business Overview
2.5.2 Multiple Myeloma Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Novartis Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Daiichi Sankyo
2.6.1 Business Overview
2.6.2 Multiple Myeloma Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Daiichi Sankyo Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Merck
2.7.1 Business Overview
2.7.2 Multiple Myeloma Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Merck Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 AB Science
2.8.1 Business Overview
2.8.2 Multiple Myeloma Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 AB Science Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Teva
2.9.1 Business Overview
2.9.2 Multiple Myeloma Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Teva Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 PharmaMar
2.10.1 Business Overview
2.10.2 Multiple Myeloma Drugs Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 PharmaMar Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Multiple Myeloma Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Multiple Myeloma Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Multiple Myeloma Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Multiple Myeloma Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 Multiple Myeloma Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Multiple Myeloma Drugs Market Analysis by Regions
4.1 Global Multiple Myeloma Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Multiple Myeloma Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global Multiple Myeloma Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
4.3 Europe Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
4.5 South America Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
5 North America Multiple Myeloma Drugs by Countries
5.1 North America Multiple Myeloma Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Multiple Myeloma Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America Multiple Myeloma Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
5.3 Canada Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
6 Europe Multiple Myeloma Drugs by Countries
6.1 Europe Multiple Myeloma Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Multiple Myeloma Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Multiple Myeloma Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
6.3 UK Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
6.4 France Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
6.5 Russia Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
6.6 Italy Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
7 Asia-Pacific Multiple Myeloma Drugs by Countries
7.1 Asia-Pacific Multiple Myeloma Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Multiple Myeloma Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Multiple Myeloma Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
7.3 Japan Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
7.4 Korea Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
7.5 India Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
8 South America Multiple Myeloma Drugs by Countries
8.1 South America Multiple Myeloma Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Multiple Myeloma Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America Multiple Myeloma Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
9 Middle East and Africa Multiple Myeloma Drugs by Countries
9.1 Middle East and Africa Multiple Myeloma Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Multiple Myeloma Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Multiple Myeloma Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
9.3 UAE Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
10 Global Multiple Myeloma Drugs Market Segment by Type
10.1 Global Multiple Myeloma Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Multiple Myeloma Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Multiple Myeloma Drugs Revenue and Market Share by Type (2013-2018)
10.2 Immunomodulatory drugs (IMiDs) Sales Growth and Price
10.2.1 Global Immunomodulatory drugs (IMiDs) Sales Growth (2013-2018)
10.2.2 Global Immunomodulatory drugs (IMiDs) Price (2013-2018)
10.3 Proteasome inhibitors Sales Growth and Price
10.3.1 Global Proteasome inhibitors Sales Growth (2013-2018)
10.3.2 Global Proteasome inhibitors Price (2013-2018)
10.4 Chemotherapy Sales Growth and Price
10.4.1 Global Chemotherapy Sales Growth (2013-2018)
10.4.2 Global Chemotherapy Price (2013-2018)
10.5 Histone deacetylase inhibitor (HDAC inhibitor) Sales Growth and Price
10.5.1 Global Histone deacetylase inhibitor (HDAC inhibitor) Sales Growth (2013-2018)
10.5.2 Global Histone deacetylase inhibitor (HDAC inhibitor) Price (2013-2018)
10.6 Steroids (corticosteroids) Sales Growth and Price
10.6.1 Global Steroids (corticosteroids) Sales Growth (2013-2018)
10.6.2 Global Steroids (corticosteroids) Price (2013-2018)
11 Global Multiple Myeloma Drugs Market Segment by Application
11.1 Global Multiple Myeloma Drugs Sales Market Share by Application (2013-2018)
11.2 Men Sales Growth (2013-2018)
11.3 Women Sales Growth (2013-2018)
12 Multiple Myeloma Drugs Market Forecast (2018-2023)
12.1 Global Multiple Myeloma Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Multiple Myeloma Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Multiple Myeloma Drugs Market Forecast (2018-2023)
12.2.2 Europe Multiple Myeloma Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Multiple Myeloma Drugs Market Forecast (2018-2023)
12.2.4 South America Multiple Myeloma Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Multiple Myeloma Drugs Market Forecast (2018-2023)
12.3 Multiple Myeloma Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Multiple Myeloma Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Multiple Myeloma Drugs Market Share Forecast by Type (2018-2023)
12.4 Multiple Myeloma Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Multiple Myeloma Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Multiple Myeloma Drugs Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Multiple Myeloma Drugs Picture
Table Product Specifications of Multiple Myeloma Drugs
Figure Global Sales Market Share of Multiple Myeloma Drugs by Types in 2017
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
